Listen
In this episode, host Alyssa Watson, DVM, welcomes Alyssa Jenkins, DVM, to talk about her recent Clinician’s Brief article, “Top 3 Recent Advances in Feline Diabetes Management.” Dr. Jenkins starts with a feline diabetes mellitus refresher, including the comparison between it and type I/type II diabetes in humans. She then details the major new things for diabetic cats: SGLT2 inhibitors, longer-acting insulins, and continuous glucose monitors.
Watch
Key Takeaways
Feline diabetes starts with insulin resistance caused by underlying factors (obesity, diet, inactivity), and it often ends with insulin dependence due to exhaustion of pancreatic production.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are novel treatment options that reduce glucose resorption in the kidneys but do not help get glucose into cells.
Patients with no history of insulin therapy are ideal candidates for an SGLT2 inhibitor, and screening includes CBC/Chem/T4/UA and serum ketones, with ketones to be rechecked 2-3 days after starting.
Insulin glargine U300 and insulin degludec mimic basal insulin activity with fewer peaks and nadirs but, unlike in humans, they are not ultra-long-acting; insulin U300 may work once daily in some cats.
Continuous glucose monitors provide numerous advantages over conventional glucose curves, including less-stressful sampling, longer sampling periods, and less physiologic disruption.
Contact:
Where To Find Us:
Website: CliniciansBrief.com/Podcasts
YouTube: Youtube.com/@clinicians_brief
Facebook: Facebook.com/CliniciansBrief
LinkedIn: LinkedIn.com/showcase/CliniciansBrief/
Instagram: @Clinicians.Brief
The Team:
Alyssa Watson, DVM - Host
Alexis Ussery - Producer & Multimedia Specialist